VRCA
Income statement / Annual
Last year (2024), Verrica Pharmaceuticals Inc.'s total revenue was $7.57 M,
an increase of 47.66% from the previous year.
In 2024, Verrica Pharmaceuticals Inc.'s net income was -$76.58 M.
See Verrica Pharmaceuticals Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$7.57 M |
$5.12 M |
$9.03 M |
$12.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$1.85 M
|
$746,000.00
|
$725,000.00
|
$472,000.00
|
$229,000.00
|
$257,199.00
|
$20,294.00
|
$0.00
|
$0.00
|
| Gross Profit |
$5.71 M
|
$4.38 M
|
$8.31 M
|
$11.53 M
|
-$229,000.00
|
-$257,199.00
|
-$20,294.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.76
|
0.85
|
0.92
|
0.96
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$11.84 M
|
$20.30 M
|
$12.20 M
|
$15.93 M
|
$15.67 M
|
$15.44 M
|
$12.83 M
|
$3.73 M
|
$1.71 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$17.41 M
|
$26.98 M
|
$24.51 M
|
$14.64 M
|
$9.05 M
|
$727,000.00
|
$204,000.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$58.82 M
|
$47.31 M
|
$17.41 M
|
$26.98 M
|
$24.51 M
|
$14.64 M
|
$9.05 M
|
$727,000.00
|
$204,000.00
|
| Other Expenses |
$970,000.00
|
$2.54 M
|
-$58,000.00
|
$0.00
|
-$1,000.00
|
$1.87 M
|
-$1,000.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$71.63 M
|
$70.14 M
|
$29.60 M
|
$42.91 M
|
$40.18 M
|
$30.08 M
|
$21.88 M
|
$4.46 M
|
$1.91 M
|
| Cost And Expenses |
$73.49 M
|
$70.88 M
|
$30.33 M
|
$42.91 M
|
$40.18 M
|
$30.08 M
|
$21.88 M
|
$4.46 M
|
$1.91 M
|
| Interest Income |
$1.42 M
|
$2.74 M
|
$476,000.00
|
$123,000.00
|
$521,000.00
|
$1.88 M
|
$1.23 M
|
$0.00
|
$0.00
|
| Interest Expense |
$9.41 M
|
$3.96 M
|
$2.17 M
|
$4.30 M
|
$3.03 M
|
$0.00
|
$0.00
|
$2,000.00
|
$0.00
|
| Depreciation & Amortization |
$1.27 M
|
$836,000.00
|
$718,000.00
|
$472,000.00
|
$229,000.00
|
$257,199.00
|
$20,294.00
|
$4.46 M
|
$1.91 M
|
| EBITDA |
-$65.90 M |
-$62.20 M |
-$21.60 M |
-$30.31 M |
-$39.43 M |
-$30.08 M |
-$20.63 M |
-$4.46 M |
-$1.91 M |
| EBITDA Ratio |
-8.71
|
-12.14
|
-2.31
|
-2.57
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-8.71
|
-12.83
|
-2.36
|
-2.58
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$10.66 M
|
-$1.24 M
|
-$3.19 M
|
-$4.17 M
|
-$2.51 M
|
$1.87 M
|
$1.23 M
|
-$2,000.00
|
$0.00
|
| Income Before Tax |
-$76.58 M
|
-$67.00 M
|
-$24.49 M
|
-$35.08 M
|
-$42.69 M
|
-$28.21 M
|
-$20.65 M
|
-$4.46 M
|
-$1.91 M
|
| Income Before Tax Ratio |
-10.12
|
-13.07
|
-2.71
|
-2.92
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$3.19 M
|
$3.82 M
|
$2.80 M
|
-$257,000.00
|
$1.23 M
|
-$4.46 M
|
-$1.91 M
|
| Net Income |
-$76.58 M
|
-$67.00 M
|
-$27.68 M
|
-$38.90 M
|
-$45.50 M
|
-$27.95 M
|
-$20.65 M
|
-$4.46 M
|
-$1.91 M
|
| Net Income Ratio |
-10.12
|
-13.07
|
-3.06
|
-3.24
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.48 |
-1.48 |
-0.81 |
-1.44 |
-1.82 |
-1.12 |
-1.41 |
-0.22 |
-0.0959 |
| EPS Diluted |
-1.48 |
-1.48 |
-0.81 |
-1.44 |
-1.82 |
-1.12 |
-1.41 |
-0.22 |
-0.0959 |
| Weighted Average Shares Out |
$51.81 M
|
$45.34 M
|
$34.16 M
|
$27.04 M
|
$25.00 M
|
$24.90 M
|
$14.66 M
|
$19.95 M
|
$19.95 M
|
| Weighted Average Shares Out Diluted |
$51.81 M
|
$45.34 M
|
$34.16 M
|
$27.04 M
|
$25.00 M
|
$24.90 M
|
$14.66 M
|
$19.95 M
|
$19.95 M
|
| Link |
|
|
|
|
|
|
|
|
|
